(Bayer) July 18, 2019 - Bayer, Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer's kinase inhibitor Stivarga® (regorafenib) and Bristol-Myers Squibb's / Ono's anti-PD-1 immune checkpoint inhibitor,...

(ESMO World GI 2019) July 6, 2019 - Medical oncologists administer anticancer drug regorafenib to try to improve overall survival in patients with metastatic colorectal cancer who have ceased to respond to standard therapy (known as refractory mCRC). However, some of the adverse events related to the use of this drug often limits its...